Acute Glucose Fluctuations and Chronic Sustained Hyperglycemia as Risk Factors for Cardiovascular Diseases in Patients with Type 2 Diabetes

Abstract

Chronic hyperglycemia, usually assessed from HbA1c determinations, results in excessive glycation and generation of oxidative stress. As a consequence, chronic hyperglycemia has been identified as a risk factor for diabetes complications leading to accelerated atherosclerosis. Both fasting and postprandial hyperglycemia contribute to this process. However the acute glucose fluctuations that occur in diabetes have been recently described as an additional factor that activates the oxidative stress. As a consequence, acute glucose swings, including upward (postprandial) and downward (interprandial) fluctuations can be considered as risk factors for cardiovascular events and should be included in the “dysglycemia” of diabetes in combination with fasting and postprandial hyperglycemia. As postprandial glucose is a contributor of both acute glucose fluctuations and chronic sustained hyperglycemia, it remains difficult to know whether these 2 mechanisms are equivalent or not equivalent risk factors for cardiovascular disease.

Type 2 diabetes - chronic hyperglycemia - acute glucose fluctuations

References

• 1 Laakso L, Lehto S. Epidemiology of macrovascular disease in diabetes.  Diabetes Rev. 1997;  5 294-315
• 2 The Diabetes Control and Complications Trial Research Group. . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 3 Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. the UK Prospective Diabetes Study Group . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  BMJ. 2000;  321 405-412
• 4 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
• 5 Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.  Diabetes Care. 1997;  20 1822-1826
• 6 El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Philipps LS. Utility of casual postprandial glucose levels in type 2 diabetes management.  Diabetes Care. 2004;  27 335-339
• 7 Rohlfing CL, Wiedmeyer HS, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c.  Diabetes Care. 2002;  25 275-278
• 8 American Diabetes Association. . Standards of medical care in diabetes-2007.  Diabetes Care. 2007;  30 ((Suppl 1)) S4-S41
• 9 Sacks DB, Bruns DE, Goldstein DE, Mac Laren NK, Mac Donald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement).  Diabetes Care. 2002;  25 750-786
• 10 Gorus F, Mathieu C, Gerlo E. How should HbA1c measurements be reported?.  Diabetologia. 2006;  49 7-10
• 11 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up.  Diabetologia. 1996;  39 1577-1583
• 12 Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Postprandial glucose regulation and diabetic complications.  Arch Int Med. 2004;  164 2090-2095
• 13 Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.  J Clin Endocrinol Metab. 2006;  91 813-819
• 14 Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by non-cyclooxygenase free radical-catalyzed mechanism.  Proc Natl Acad Sci USA. 1991;  87 9383-9387
• 15 Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo.  Free Radic Bio Med. 2000;  28 505-513
• 16 Basu S. Metabolism of 8-iso-prostaglandin F2α.  FEBS Lett. 1998;  428 32-36
• 17 Davi G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus.  Antioxid Redox Signal. 2005;  7 256-258
• 18 Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.  JAMA. 2006;  295 1681-1687
• 19 Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Cotantini F, Capani F, Patrono C. In vivo formation of 8-Iso-Prostaglandin F2α and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation.  Circulation. 1999;  99 224-229
• 20 Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2 Isoprostanes. Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes.  Diabetes Care. 2002;  25 537-541
• 21 Ceriello A. Postprandial hyperglycemia and diabetes complications. Is it time to treat?.  Diabetes. 2005;  54 1-7
• 22 Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation.  Diabetes Care. 2002;  25 1439-1443
• 23 Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.  Diabetes Care. 2006;  29 1486-1490

Correspondence